ArticleEndocrine2025
Number of comorbidities predicts adrenal incidentaloma and autonomic cortisol secretion in obese individuals: A two-center cohort study.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Plasma cortisol cut-off concentrations using the dexamethasone suppression test in patients with adrenal incidentalomas.Frontiers in endocrinology · 2026Observational
- Alternative cutoffs for cortisol post-Dexamethasone suppression testing: is there a practical point for the bone health evaluation?Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe objective of this study was to investigate the association between number of comorbidities (NOC) with adrenal incidentaloma (AI) and autonomic cortisol hypersecretion (ACS) in obese individuals.
methodsThis cohort study included 855 obese individuals (males/females: 175/680), who presented with obesity and were screened with 1 mg dexamethasone suppression test (DST). Hypertension (HT); type 2 diabetes mellitus (T2DM); hyperlipidaemia (HL); coronary artery disease (CAD); frequency of AI (in 255 patients with imaging) data were obtained from patient files. Patients were categorized according to DST cortisol levels as <0.9 μg/dL (group 1 [G1]), 0.9-1.8 μg/dL (G2) and >1.8 μg/dL (G3, defined as ACS).
resultsFrequency of ACS and AI according to NOC; NOC-0 (0.5%, 2.5%), NOC-1 (0.9%, 15.8%), NOC-2 (3.4%, 23.5%), NOC-3 (4.1%, 15.1%), NOC-4 (13.6%, 35.7%). Increased frequency of ACS and AI in NOC-2, NOC-3, NOC-4 vs. NOC-0 group (P < 0.05 for all). The prevalence of T2DM, HT, HL CAD and AI was lower in the group with a G1 (18.5%, 19.5%, 31.7%, 3.6%, 3%) compared to those in the G2 (43.8%, 70.5%, 52.7%, 12.5%, 52.4%, P < 0.001 for all) and G3 (42.9%, 78.6%, 78.6%, 21.4%, 61.5%, P < 0.001 for all), frequency of comorbidities and AI in G2 vs. G3 are similar. DST result was found to be an independent factor the presence of any comorbidity.
conclusionIn obese individuals, NOC-2 and higher levels are associated with an increased incidence of AI and ACS. DST is a simple and reliable test to demonstrate this association, and a cut-off of 0.9 μg/dL may be more sensitive.
Indexed as
Identifiers
40736619What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.